TY - JOUR AU - Chowdary, Sravya AU - Panigrahy, Uttam Prasad AU - Abbulu, Konde PY - 2019/07/28 Y2 - 2024/03/29 TI - PIBRENTASVIR – A REVIEW JF - Innoriginal: International Journal of Sciences JA - IIJS VL - 0 IS - 0 SE - REVIEW ARTICLES DO - UR - https://innoriginal.com/index.php/iijs/article/view/225 SP - 1-4 AB - <p>Pibrentasvir will come under Anti-viral drugs. It will be available as Brand name – Mavyret (Combination of Pibrentasvir &amp; Glecaprevir).It is indicated for the treatment of adult patients with chronic Hepatitis C virus (HCV). Mavyret is contraindicated to the Patients with severe hepatic impairment (Child-Pugh C) and to the drugs like Rifampin or Atazanavir. The common adverse effects are Headache and fatigue. It is an NS5A inhibitor. It mainly works by blocking the interaction with the viral capsid protein, it inhibits the assembly of proteins &amp; formation of HCV particles. In the present work, the developed method Chromatogram was run through  Kinetics Phenyl Hexyl C8 (150×4.6) mm, 2.6µm. Mobile phase contains a mixture of Buffer: ACN (70:30) was pumped through a flow rate of 1.0mL/min. Buffer used in this method was 0.01M of Potassium Di hydrogen phosphate in 1L of Milli Q water, pH to 2.8 with diluted OPA. Temperature of column and sample was maintained at 30<sup>0</sup>C &amp; 25<sup>0</sup>C respectively. Optimized wavelength selected was 252nm.Retention time of pibrentasvir was found to be 38.454 min. % RSD of the pibrentasvir was found to be 0.9999. % Recovery was found to be 99.73 to 101.15 %.</p> ER -